Production (Stage)
Eton Pharmaceuticals, Inc.
ETON
$14.30
-$0.21-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.28M | 11.65M | 10.32M | 9.07M | 7.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.28M | 11.65M | 10.32M | 9.07M | 7.97M |
| Cost of Revenue | 7.42M | 5.17M | 4.02M | 3.45M | 2.96M |
| Gross Profit | 9.86M | 6.48M | 6.30M | 5.63M | 5.01M |
| SG&A Expenses | 9.17M | 6.30M | 5.29M | 5.59M | 5.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.75M | 10.60M | 9.82M | 12.01M | 8.77M |
| Operating Income | -470.00K | 1.04M | 509.00K | -2.94M | -800.00K |
| Income Before Tax | -1.50M | -511.00K | 501.00K | -2.99M | -811.00K |
| Income Tax Expenses | 74.00K | 87.00K | -126.00K | 54.00K | -- |
| Earnings from Continuing Operations | -1.57M | -598.00K | 627.00K | -3.04M | -811.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.57M | -598.00K | 627.00K | -3.04M | -811.00K |
| EBIT | -470.00K | 1.04M | 509.00K | -2.94M | -800.00K |
| EBITDA | 543.00K | 1.33M | 787.00K | -2.66M | -566.00K |
| EPS Basic | -0.06 | -0.02 | 0.02 | -0.12 | -0.03 |
| Normalized Basic EPS | -0.03 | 0.00 | 0.01 | -0.07 | -0.02 |
| EPS Diluted | -0.06 | -0.03 | 0.02 | -0.12 | -0.03 |
| Normalized Diluted EPS | -0.03 | 0.00 | 0.01 | -0.07 | -0.02 |
| Average Basic Shares Outstanding | 26.89M | 26.14M | 25.90M | 25.78M | 25.76M |
| Average Diluted Shares Outstanding | 26.89M | 26.14M | 26.55M | 25.78M | 25.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |